This Article Full Text (OnlineFirst PDF) All Versions of this Article: 1078155208100095v1 15/2/95    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Boehnke Michaud, L. Search for Related Content PubMed PubMed Citation Articles by Boehnke Michaud, L. Social Bookmarking                         What's this?

The optimal therapeutic use of ixabepilone in patients with locally advanced or metastatic breast cancer

University of Texas, MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA

^* To whom correspondence should be addressed.

	Abstract

Background. The epothilones are a new class of microtubule-stabilizing drugs that exert potent antitumor activity against taxane-resistant and multidrug resistant cell lines. The most clinically advanced member of this class is the semisynthetic epothilone B derivative ixabepilone.

Purpose. This article reviews the preclinical and clinical data on ixabepilone in patients with locally advanced and metastatic breast cancer (MBC) and provides guidance for pharmacists on its optimal use.

Data sources. PubMed and conference proceedings through August 2008.

Results. In preclinical studies, ixabepilone has demonstrated potent antitumor activity and low susceptibility to mechanisms that confer tumor resistance. Clinically meaningful benefits have been achieved with ixabepilone monotherapy in phase 2 trials of patients with MBC who have failed previous chemotherapies (anthracyclines, taxanes, or capecitabine). In a randomized, phase 3 trial, the combination of ixabepilone and capecitabine proved more effective than capecitabine alone after the failure of taxane and anthracycline regimens. At the recommended dose and schedule, the therapeutic ratio of ixabepilone is generally favorable, and its adverse effects (notably neutropenia and peripheral neuropathy) are generally manageable and reversible.

Conclusion. Ixabepilone represents an advance in the treatment of anthracycline - and taxane-pretreated MBC. Future studies will define its efficacy in combination with other drugs used in the treatment of MBC, as well as in other types of cancer.

Key Words: ixabepilone; epothilones; microtubule-stabilizing agents; metastatic breast cancer

First published on January 26, 2009, doi:10.1177/1078155208100095

Journal of Oncology Pharmacy Practice 2009;15:95.

A more recent version of this article appeared on June 1, 2009


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				J. Schwartz Current combination chemotherapy regimens for metastatic breast cancer Am. J. Health Syst. Pharm., December 1, 2009; 66(23_Supplement_6): S3 - S8. [Abstract] [Full Text] [PDF]